CytRx Reports Third Quarter 2012 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2012. The Company also announced that it has held a positive meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential Phase 3 pivotal trial with aldoxorubicin (formerly INNO-206) as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy.

“We are planning to submit a special protocol assessment (SPA) for the Phase 3 trial in patients with advanced soft tissue sarcomas,” said President and Chief Executive Officer Steven A. Kriegsman. “An agreement with the FDA with regards to an SPA would provide a clear regulatory pathway through the approval process. The initiation of a Phase 3 program for our lead drug candidate aldoxorubicin would represent a significant milestone in CytRx’s efforts to bring value to our stockholders and for those patients suffering from soft tissue sarcoma.”

The SPA process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a New Drug Application (NDA). Final marketing approval by the FDA depends on the results of the trial.

CytRx had previously announced its intention to pursue a Phase 3 pivotal trial with its tumor-targeting doxorubicin conjugate aldoxorubicin in patients with advanced soft tissue sarcomas, supported in part by positive data from a Phase 1b/2 clinical trial. Clinical results from the Phase 1b/2 trial were featured in presentations at the prominent American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) conferences within the past five months and will soon be presented at the Connective Tissue Oncology Society (CTOS) conference in Prague, Czech Republic.

“Having raised more than $21 million in net proceeds from a public offering completed late last month, we believe our capital resources are sufficient to fund our operations through the foreseeable future,” added Mr. Kriegsman. “We are well positioned to advance the development of our promising oncology drug candidates in multiple indications and we expect to reach major inflection points in several clinical trials in the coming year.”

Third Quarter 2012 Financial Results

CytRx reported net income for the quarter ended September 30, 2012 of $1.6 million, or $0.07 per share, compared with a net loss of $0.6 million, or $0.03 per share, for the quarter ended September 30, 2011. The $2.2 million improvement was due principally to a $6.4 million gain on warrant derivative liability, attributable primarily to the warrants issued in connection with the August 2011 equity financing, compared with a $4.3 million gain on warrant derivative liability for the third quarter of 2011. The Company did not report revenue for either the third quarter of 2012 or 2011.

Research and development (R&D) expenses were $3.2 million for the third quarters of 2012 and 2011. R&D expenses for the third quarter of 2012 included $1.7 million in development expenses for aldoxorubicin and $0.7 million in expenses for tamibarotene.

General and administrative (G&A) expenses of $1.7 million for the third quarter of 2012 were relatively unchanged from the third quarter of 2011. G&A expenses included non-cash stock-compensation expense of $0.4 million and $0.2 million for the third quarters of 2012 and 2011, respectively.

CytRx reported cash, cash equivalents and short-term investment of $22.5 million as of September 30, 2012, compared with $36.0 million as of December 31, 2011. Subsequent to September 30, 2012, the Company raised $21.4 million of net proceeds from an underwritten public offering completed on October 23, 2012, which further increased the cash available for operations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors, a Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company has held a positive meeting with the FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and is planning to submit a special protocol assessment related to this trial in the fourth quarter of 2012. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the outcome, timing and results of CytRx's clinical trials with aldoxorubicin and tamibarotene, the risk that any future human testing of aldoxorubicin or tamibarotene might not produce results similar to those seen in the Company's prior animal or human trials, uncertainties regarding regulatory approvals for current and future clinical testing, including CytRx's planned Phase 3 clinical trial for aldoxorubicin, and the scope of the clinical testing that may eventually be required by regulatory authorities, the risk that aldoxorubicin might not show greater efficacy than doxorubicin notwithstanding the administration of higher doses than the standard of care, the risk that additional longer-term dosing of aldoxorubicin might cause adverse events not seen to date in CytRx's Phase 1b/2 trial, uncertainties regarding whether aldoxorubicin effectively targets doxorubicin to tumors, the significant time and expense that will be incurred in developing any of the potential commercial applications for aldoxorubicin or tamibarotene, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



September 30, 2012 December 31, 2011
Current assets:
Cash and cash equivalents $ 12,453,637 $ 17,988,590
Short-term investments 10,000,000 18,057,672
Receivable 82,899 175,704
Interest receivable 25,605 41,275
Prepaid expenses and other current assets   1,200,084     1,017,799  
Total current assets 23,762,225 37,281,040
Equipment and furnishings, net 302,316 266,335
Goodwill 183,780 183,780
Other assets   110,469     123,268  
Total assets $ 24,358,790   $ 37,854,423  

Current liabilities:
Accounts payable $ 2,584,977 $ 2,074,463
Accrued expenses and other current liabilities 5,297,089 4,786,956
Warrant liabilities   12,718,950     6,738,934  
Total current liabilities   20,601,016     13,600,353  
Stockholders’ equity (2011 restated to reflect a 1-for-7 reverse common stock split, see Note 1):
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding
Common stock, $.001 par value, 250,000,000 shares authorized; 21,307,916 shares issued and outstanding at September 30, 2012 and 21,294,413 shares issued and outstanding at December 31, 2011 21,308 21,294
Additional paid-in capital 238,769,155 237,452,308
Treasury stock, at cost (90,546 shares) (2,279,238 ) (2,279,238 )
Accumulated deficit   (232,753,451 )   (210,940,294 )
Total stockholders’ equity   3,757,774     24,254,070  
Total liabilities and stockholders’ equity $ 24,358,790   $ 37,854,423  




Three Months Ended

September 30,

Nine Months Ended

September 30,




License revenue $   $   $   $ 150,000  

Research and development 3,157,656 3,220,098 10,245,637 9,927,458
General and administrative   1,729,893     1,739,148     5,736,464     5,913,209  
  4,887,549     4,959,246     15,982,101     15,840,667  
Loss before other income (4,887,549 ) (4,959,246 ) (15,982,101 ) (15,690,667 )
Other income:
Interest income 25,034 56,452 88,039 162,151
Other income, net 10,370 28,468 60,921 81,118
Gain (loss) on warrant derivative liability   6,436,342     4,316,560     (5,980,016 )   5,494,322  
Income (loss) before provision for income taxes 1,584,197 (557,766 ) (21,813,157 ) (9,953,076 )
Provision for income taxes                
Net income (loss) $ 1,584,197   $ (557,766 ) $ (21,813,157 ) $ (9,953,076 )
Other comprehensive income (net of tax)

Unrealized gain (loss) on available-for-sale securities
      (263,340 )       115,920  
Comprehensive income (loss) $ 1,584,197   $ (821,106 ) $ (21,813,157 ) $ (9,837,156 )
Basic net income (loss) per share $ 0.07   $ (0.03 ) $ (1.03 ) $ (0.59 )
Basic weighted average shares outstanding   21,208,660     19,256,041     21,208,960     16,834,600  
Diluted net income (loss) per share $ 0.07   $ (0.03 ) $ (1.03 ) $ (0.59 )
Diluted weighted average shares outstanding   21,724,986     19,256,041     21,208,960     16,834,600  

Copyright Business Wire 2010